vqe-active-space-drug-benchmark

name	vqe-active-space-drug-benchmark
description	Systematic benchmark methodology for active space selection in VQE-driven quantum drug discovery pipelines. Classifies molecule suitability for quantum computing using chemically grounded metrics, evaluates VQE across UCCSD and HEA ansatze with both simulation and QPU execution on drug-like molecules (lovastatin, oseltamivir, morphine).
version	1.0.0
category	quantum-medical
activation_keywords	["VQE active space","quantum drug discovery","active space benchmark","UCCSD drug molecule","HEA ansatz drug","molecular suitability quantum","VQE pipeline benchmark","lovastatin quantum","oseltamivir quantum"]
last_updated	2026-06-17T00:00:00.000Z
source	arxiv:2512.18203

VQE Active Space Selection Benchmark for Drug Discovery

Source

Paper: "Benchmarking the Impact of Active Space Selection on the VQE Pipeline for Quantum Drug Discovery" arXiv: 2512.18203 (December 2025) Authors: Zhi Yin, Xiaoran Li, Zhupeng Han, Shengyu Zhang, Xin Li, Zhihong Zhang, Runqing Zhang, Anbang Wang, Xiaojin Zhang

Problem Statement

Applying Variational Quantum Eigensolvers (VQE) to realistic drug-like molecules on NISQ hardware remains challenging. Active space selection is a key strategy to leverage current hardware effectively, yet remains under-benchmarked. This work introduces the first systematic benchmark for active space-driven VQE in quantum drug discovery.

Methodology

Molecule Suitability Classification

Heuristic criteria based on chemically grounded metrics to classify whether a molecule is suitable for quantum computing:

1. Electronic Structure Complexity: Number of correlated electrons, orbital degeneracy
2. Active Space Size: Feasible qubit count for NISQ hardware (typically 10-30 qubits)
3. Chemical Significance: Presence of pharmacophores, reactive centers, metal centers
4. Classical Intractability: Cases where classical methods (DFT, CCSD(T)) struggle

Benchmark Molecules

• Lovastatin: Statin drug, complex ring system
• Oseltamivir: Antiviral (Tamiflu), amine-containing
• Morphine: Opioid analgesic, complex polycyclic structure

VQE Evaluation Setup

Ansätze Tested:

• UCCSD: Unitary Coupled Cluster with Singles and Doubles (chemistry-accurate but deep circuits)
• HEA: Hardware-Efficient Ansatz (shallower, hardware-friendly but less chemically motivated)

Execution Modes:

• Statevector Simulation: Noiseless baseline
• QPU Execution: Real quantum hardware with noise

Evaluation Metrics:

• Chemistry metrics: Energy error vs FCI/CCSD(T) reference, dissociation curve accuracy
• Architecture metrics: Circuit depth, parameter count, gate count, hardware compatibility

Active Space Selection Strategies

1. Chemically Motivated: Domain-expert selection based on molecular orbital analysis
2. Automated Heuristic: Algorithmic selection based on orbital energy gaps, occupation numbers
3. Comparative Analysis: Systematic comparison across active space sizes

Implementation Steps

1. Molecule Selection: Choose drug-like molecules with known pharmacological relevance
2. Classical Pre-computation: Run HF/DFT to obtain molecular orbitals
3. Active Space Selection: Apply heuristic criteria to select active orbitals
4. VQE Setup: Configure UCCSD and HEA ansätze for each active space
5. Execution: Run on simulator and QPU
6. Evaluation: Compare energy accuracy, circuit complexity, hardware performance
7. Benchmark Report: Classify molecules by quantum readiness

Key Insights

UCCSD vs HEA Trade-offs

• UCCSD: Higher accuracy but deeper circuits, more prone to noise on real hardware
• HEA: Shallower circuits, better hardware performance but less chemical accuracy
• Active space size critically affects both: larger spaces need UCCSD for accuracy but may exceed hardware limits

Hardware-Algorithm Co-Design

• Active space selection should consider target hardware constraints (qubit count, connectivity, coherence time)
• Different molecules require different active space strategies based on their electronic structure

Pitfalls

1. Active Space Too Small

Problem: Missing important correlation effects, inaccurate energies. Solution: Use chemical intuition + automated heuristics to ensure all relevant orbitals are included.

2. Active Space Too Large

Problem: Circuit depth exceeds NISQ capabilities, noise destroys results. Solution: Benchmark molecule suitability before committing to VQE.

3. HEA Ansatz Chemical Accuracy

Problem: HEA may not capture correct chemical physics even with enough parameters. Solution: Use UCCSD for accuracy-critical applications, HEA for hardware-feasibility studies.

4. Reference Method Selection

Problem: Need reliable classical reference (FCI, CCSD(T)) to evaluate VQE accuracy. Solution: Use CCSD(T) for drug-sized molecules where FCI is intractable.

Verification

• VQE energy should converge to classical reference as active space increases
• UCCSD should be more accurate than HEA on simulators
• HEA should be more robust on real QPU hardware
• Active space selection criteria should correctly predict molecule suitability for quantum computing

Related Skills

• vqe-active-space-benchmarking
• quantum-drug-discovery
• quantum-chemistry
• dft-embedded-quantum-chemistry